Kytopen Elects Industry Veterans to Board, Further Demonstrating its Commitment to Enabling Advanced Engineered Cell Therapy Workflows

• Kytopen appoints new board of directors as part of its commercial expansion of the Flowfect Tx^® GMP cellular engineering platform.
• Industry veteran Henry Hebel joins Kytopen's board bringing operational expertise from Aldevron.
• Joe Gentile, recognized life sciences leader and former board observer, elected Chairman of the Board.

CAMBRIDGE, Mass., June 3, 2025 /PRNewswire/ -- Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies today announced the appointment of Henry Hebel and Joe Gentile to its Board of Directors, effective immediately. Joe Gentile, previously a board observer, has been named Chairman of the Board. These appointments mark a key milestone in Kytopen's strategic growth, as the company scales the Flowfect Tx^® GMP platform to deliver on its mission to transform how cell therapies are manufactured — maximizing yields, delivering hundreds of billions of healthy, engineered cells in minutes.

Henry Hebel brings a wealth of operational and leadership experience to the board. He most recently served as Chief Operating Officer at Aldevron, a leading provider of plasmid DNA and other biological products and has deep roots in the life sciences industry. His deep operational knowledge in the life sciences space will help guide Kytopen through its next phase of growth. Joe Gentile, who has held executive and board-level positions for over 30 years across the medical device, diagnostics, and life science tools sectors, steps into the Chairman role to help guide Kytopen's continued commercial expansion and operational execution. In his new capacity as Board Chair, Joe will help steer Kytopen's strategic direction and oversee continued operational excellence.

"Joe and Henry are visionary leaders who will support us in keeping a laser focus on results while pushing the boundaries of innovation to deliver on the promise of our continuous flow technology," said Michael Chiu, CEO of Kytopen "Their industry expertise is invaluable as we navigate this exciting period of growth and transformation." 

"I am thrilled to join the board and look forward to working with the talented team at Kytopen to drive the company's future success," said Henry Hebel. "I am especially excited about the promise of the Flowfect^® technology to accelerate the discovery, development, and manufacture of advanced engineered cell therapies."

"I am honored to take on the role as Chairman of the Board and to support Kytopen's bright future," added Joe Gentile.  "Our focus on operational excellence and commercial expansion will be central to delivering on the promise of our platform. I also want to thank the former board members for their leadership and partnership during this transition."

Kytopen's leadership expansion, along with its continued innovation through the proprietary Flowfect^® technology, reinforces the company's dedication to advancing engineered cell therapy workflows and improving access to potentially life-saving treatments.

For further information:

Kytopen:

Investor Contact:
Michael Chiu PhD., CEO
[email protected]

Business and Corporate Development Contact:
Kevin Gutshall, CCO
[email protected]

About Kytopen:

The innovative leader in non-viral, continuous flow cellular engineering technologies, Kytopen, headquartered in Cambridge, Massachusetts, is transforming how cell therapies are manufactured by maximizing yields, delivering hundreds of billions of engineered cells in minutes – faster than any other technology – and thereby accelerating the discovery, development, and manufacture of advanced engineered cell therapies. Its Flowfect^® cellular engineering technology is highly tunable, gentle on cells, and has demonstrated performance across a range of cell types, payloads, and therapeutic applications. Kytopen has recently disclosed strategic partnerships with industry-leading biotechnology companies, contract development and manufacturing organizations (CDMOs), and cell therapy-focused medical centers. Kytopen continues to engage strategic partners and is committed to enabling their partners' success by providing innovative technology and developing close collaborative relationships to bring lifesaving, next generation cell therapies to patients worldwide. www.kytopen.com

SOURCE Kytopen